Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
33%(3 trials)

Phase Distribution

Ph phase_2
2
18%
Ph not_applicable
3
27%
Ph phase_3
1
9%
Ph phase_4
3
27%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
3(27.3%)
N/ANon-phased studies
3(27.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 22 (18.2%)
Phase 31 (9.1%)
Phase 43 (27.3%)
N/A3 (27.3%)

Trials by Status

completed982%
withdrawn19%
unknown19%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

NCT05974267
completedphase_1

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

NCT06294912
unknownphase_4

The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia

NCT02297477
withdrawnnot_applicable

A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)

NCT04203186
completedphase_1

Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1

NCT02836002
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05974267Phase 2

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Completed
NCT06294912Phase 1

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Completed
NCT02297477Phase 4

The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia

Unknown
NCT04203186Not Applicable

A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)

Withdrawn
NCT02836002Phase 1

Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1

Completed
NCT02098590Not Applicable

Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection

Completed
NCT02080026Not Applicable

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis

Completed
NCT00379821Phase 3

Chloroquine Alone or in Combination for Malaria in Children in Malawi

Completed
NCT00084227Phase 2

Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America

Completed
NCT00444106Phase 4

Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function

Completed
NCT00451139Phase 4

Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11